Expanded Access Policy

At COUR, we are dedicated to developing innovative therapies to address the unmet medical needs of individuals living with autoimmune diseases.

Our current programs include CNP-103 for Type 1 Diabetes and CNP-104 for Primary Biliary Cholangitis. Our mission is to make our investigational medicines available at the right time and in the way that offers the most benefit to patients. We believe the most appropriate and secure way to do this is through participation in our clinical trials.

We understand that not all patients will qualify for our clinical studies and may be interested in expanded access to investigational therapies. Unfortunately, at this time, COUR is not able to provide access to investigational medicines outside of a clinical trial setting.

We encourage patients and healthcare providers to explore ongoing clinical trials by visiting the clinical trial section of our website at or by visiting www.clinicaltrials.gov.

^*note that COUR may update its expanded access policy as circumstances evolve.

For any questions related to our clinical trials, please contact us at clinicaltrials@courpharma.com.